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Abstract
Rationale: Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by excessive deposition of
extracellular matrix (ECM).
Objectives: We investigated the regulation of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lung
fibrosis.
Methods: MMP and TIMP expression, collagenolytic activity and collagen content was assessed in IPF (n=16)
versus donor (n=6) lung homogenates and accomplished by in-situ-zymography for gelatinolytic and collagenolytic
activities, combined with MMP antigen detection. Role of MMP13 was assessed employing the bleomycin model of
lung fibrosis in MMP-13-/- versus wild-type mice.
Measurements and Main Results: In IPF, MMPs-1, 2, 7, 9 and 13, but not MMP-8, were significantly upregulated,
whereas none of the TIMPs (1–4) were significantly altered. Collagen content was slightly increased and
collagenolytic activity was most prominent in the airways and co-localized with MMP-13. We observed an
exaggerated early inflammatory response and an augmented lung fibrosis in bleomycin-challenged MMP-13-/- versus
wild-type mice, with elevated lung collagen content 28d after bleomycin challenge in the MMP-13-/- mice.
Conclusions: Our data suggest that i) collagen deposition in IPF lungs is not primarily due to excessive TIMP
production, but rather due to overwhelming ECM production in face of an overall increased, but spatially imbalanced
collagenolytic activity, ii) preferential distribution of collagenolytic activity, largely MMP-13, in the airways offers an
explanation for the development of honeycomb cysts and iii) despite an overall increase in inflammatory cell content
the presence of MMP-13 seems to limit the overall extent of ECM deposition in lung fibrosis.
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Introduction
Pulmonary fibrosis is a devastating and ultimately fatal
disease of unknown etiology [1]. According to an increasingly
favored theory, chronic epithelial injury and disturbed epithelial-
mesenchymal interactions underlie excessive interstitial
deposition of collagen and consecutive loss of normal lung
parenchyma [1] An imbalance of matrix metalloproteinases
(MMPs) and their inhibitors, the tissue inhibitors of
metalloproteinases (TIMPs) are believed to significantly
contribute to the pathogenesis of pulmonary fibrosis [2] MMPs
are a family of inducible, zinc-dependent, secreted or cell
surface based endopeptidases that are centrally involved in the
turnover of extracellular matrix (ECM) components such as
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e73279
collagens and proteoglycans. They play a role in several
biological processes such as embryogenesis, control of tissue
remodeling, wound healing and angiogenesis [1,2]. MMP
activity is tightly regulated at several levels including
transcription and translation, compartmentalization, and
inhibition by their endogenous inhibitors, the TIMPs [3]. MMPs
have been implicated in various pathologies including
cardiovascular diseases [4], rheumatoid and osteoarthritis [5],
nephritis [6], cancer and metastasis [7], tissue ulcers [8],
fibrosis [9–11] and more. The gelatinases (MMP-2 and -9) and,
in particular, MMP-7, have already been suggested to play a
role in human and experimental lung fibrosis, thus
underscoring the dynamic regulation of the ECM and of
remodeling processes in the lung [11], MMP-1 is lacking in
rodents, and, hence, MMP-13 (also known as collagenase-3) is
the principal interstitial collagenase in this species and has a
high specificity for degrading insoluble fibrillar collagens,
especially type II and I collagens [12,13]. The expression of
MMP-8 and -13 was shown to be down-regulated in a model of
pulmonary fibrosis induced in rats with paraquat and hyperoxia
[14]. Whereas MMP-13 was recently shown to play a role in the
pathogenesis of liver fibrosis [13,15], the role of MMP-13 in
lung fibrosis remains to be established.
In the present study, we therefore assessed the regulation of
several MMPs in human lung tissues from 16 patients with
sporadic IPF and 6 organ donors. We identified MMP-7 and the
collagenases MMP-1 and MMP-13 as key MMPs upregulated
in human IPF. Because mice lack the orthologue of human
MMP-1 and in view of our clinical data, we further investigated
the role of MMP-13 in the murine model of bleomycin-induced
lung fibrosis. In response to bleomycin challenge and
compared with wild-type (WT) mice, MMP-13-/- mice exhibited
an increased inflammatory reaction and a greater extent of
fibrosis. MMP-13 thus appears to be centrally involved in the
regulation of ECM turnover and collagen deposition in both
mice and man.
Methods
Study Population and Specimen Collection
The study protocol was approved by the Ethics Committee of
the Justus-Liebig-University School of Medicine (No. 31/93,
84/93, 29/01) and provision of patients biospecimen was
approved by the University of Vienna Hospital ethics committee
(EK-Nr 076/2009). A written informed consent was obtained
from all study subjects. Diagnosis of sporadic IPF was made
according to [16] and a usual interstitial pneumonia (UIP)
pattern was proven in all 16 explanted lungs. Mean age of the
patients was 50.2 +/- 15.6 years. Non-utilized control lungs or
lobes from donors fulfilled transplantation criteria (n = 6;
controls, mean age 36.2 +/- 10.7 years). For RNA analysis two
additional control samples were included: 1) a pool of total
RNA from six lungs purchased from Clontech (Mountain View,
CA) and 2) total RNA from one lung from Ambion (Austin, TX).
IPF lung tissue
Explanted lungs of 16 patients with UIP/IPF undergoing lung
transplantation (at the Department of Thoracic Surgery,
University of Vienna Hospital, Austria) as well as 6 non-utilized
donor lungs or lobes (control) were used for this study. Already
at the surgical theatre lung tissue samples were embedded in
Tissue-Tek® OCT compound (Sakura Finetek, U.S.A, Inc.
Torrance, CA) shock-frozen in liquid nitrogen and stored at
-80°C. Of these, 10µm thick sections were cut by cryostat
(Leica), transferred onto superfrost slides, air dried and stored
at -20°C. In addition, after transferal to our site, lungs were
dissected and samples were again shock-frozen in liquid
nitrogen and stored at -80°C. With the exception of the analysis
of collagen content all peripheral tissue samples investigated in
this study originated from the basal region of the lungs. For
histology, parallel samples were fixed in 10% neutral buffered
formalin (VWR International, Darmstadt, Germany) for 72h at
room temperature. Sections were dehydrated through a series
of graded ethanol and xylene, and embedded in paraffin.
For zymography and western blot analysis lung
homogenates were prepared. Snap-frozen human lung tissue
was pulverized in liquid nitrogen and incubated in RIPA buffer
(50mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1% Triton
X-100, 1% NP-40, 0.1% SDS, 1mM PMSF, complete protease
inhibitor cocktail) (Roche Applied Science, Indianapolis, IN).
Protein concentrations were determined with the BCA Protein
Assay Kit (Pierce, Rockford, IL).
Animal Experimental Procedures
MMP-13-/- and wild type littermates in a C57BL/6J and
129/Sv hybrid background were generated from the intercross
between heterozygous MMP-13+/- mice as described elsewhere
[13]. Animal experiments were approved by the Columbia
University Institutional Animal Care and Use Committee.
Pulmonary fibrosis was induced by intratracheal administration
of a single dose of bleomycin (5U/kg bw) to age-matched and
gender-matched MMP-13-/- and WT littermates (8-10 weeks).
Control mice received 0.9% NaCl intratracheally. Mice were
euthanized 7, 14, and 28 days after challenge. Unless
otherwise specified, for every variable analyzed, five control
and five experimental mice were used. To determine the
pulmonary compliance of the lung, an open-chest model was
used as previously described [17] and the quasi-static lung
compliance was measured using the Flexivent apparatus
(Scireq Inc, Montréal, Canada). Bronchoalveolar lavage (BAL)
and analysis were performed as described elsewhere [18]. In
brief, BAL-fluid (BALF) was centrifuged at 300g for 10 minutes
at 4°C, and the supernatant was aliquoted and frozen at -80°C
until analysis. Total cell counts were performed on the cell
pellets with an improved Neubauer hemocytometer. Cells were
then cytospun at 700 rpm for 3 minutes (Cytospin 3®, Thermo
Shandon Ltd, Astm oor, U.K) and stained with a modified
Wright’s stain (DiffQuik, American Scientific Products, IL).
Differential cell counts were performed on 200 cells using
standard morphological criteria. Lungs were pressure-perfused
at 25 cmH 2O for 20 minutes followed by submersion in 10%
neutral buffered formalin for 24h at RT. Paraffin embedded
tissues were prepared and 3µm thick sections were cut as
described above. For frozen sections, murine lungs were
distended to total lung capacity with Tissue-Tek® OCT
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compound, removed en bloc, snap-frozen in liquid nitrogen and
stored at -80°C. 10µm sections were cut as described above.
Gelatin Substrate Zymography
Murine BALF and human lung homogenates were
electrophoretically separated on a denaturing, non-reducing
10% sodium dodecyl sulfate (SDS)-polyacrylamide gel
copolymerized with 1 mg/mL of porcine skin gelatin (Sigma).
After electrophoresis SDS was removed from the gels by two
washes in 2.5% Triton X-100, 30 minutes each time at RT.
Subsequently, the gels were equilibrated in developing buffer
(50 mM Tris [pH 7.4], 10 mM CaCl2, 1µM ZnCl2, 1% Triton
X-100) for 30 minutes, then incubated in fresh developing
buffer at 37°C for 18 hours. Following Coomassie staining
(0.5% Coomassie Blue R-250 for 1h) and destaining, the
gelatinolytic activity was detected as clear bands on a dark
blue background. Control gels were incubated in buffer
containing 20mM EDTA. Lytic zones were analyzed by
densitometry and quantified using AlphaEase ®FC Imaging
System (San Leandro, CA, USA). Active human MMP-2
(Catalog No. PF023) and human recombinant MMP-9 (Catalog
No. PF024), both obtained from Calbiochem, Darmstadt,
Germany were used as positive controls and BenchMarkTM pre-
stained Protein Ladder (Invitrogen, Carlsbad, California, USA)
was used as a molecular weight marker.
Hydroxyproline assay
Hydroxyproline levels in human and murine lung tissue were
determined following the protocol of Woessner [19]. The lung
tissue was homogenized in 0.5ml of distilled H2O (dH2O), then
lyophilized for 12h and the lung dry weight was measured. The
dry lung was hydrolyzed with 4ml of 6N HCl at 116°C for 16 h.
2ml of the hydrolysate were evaporated and the powder was
then reconstituted with 2ml of dH2O and then re-evaporated.
This powder was then reconstituted with 2ml of dH2O and the
pH adjusted to pH 7.0. Standard solutions containing 3, 4 D-L-
hydroxyproline (Sigma) were prepared. Sample solution (2ml)
was taken and oxidized with 1ml of Chloramine-T (Sigma) for
20 min. The reaction was then stopped with 1ml of 3.15M
perchloric acid. After 5min, 1ml of p-
dimethylaminobenzaldehyde solution was added. The sample
was thoroughly vortexed until appearing lucent, incubated in a
60°C bath for 20 minutes, and then cooled under tap water for
5min. The absorbance of the solutions was determined at
557mm. The hydroxyproline content of the lung samples was
calculated from the standard curve and expressed as mg
hydroxyproline per lung dry weight.
Real Time- Polymerase Chain Reaction
Total RNA was extracted from lung tissue using the Qiagen
RNeasy® Mini kit (Qiagen, Valencia, CA). Briefly, snap frozen
lungs were homogenized in buffer RLT containing 1% v/v β-
mercaptoethanol. After full speed centrifugation for 3 min,
supernatants were collected and mixed with an equal volume
of 70% ethanol (RNase-free). The mixture was added to an
RNeasy mini column and centrifuged again. RNase-free DNase
I was added to the filter membranes for ≥ 15 min at 20-30°C in
order to eliminate contaminating genomic DNA. Following
washes of the column, RNA was eluted from the filter using
40µl of RNase free water. The RNA concentration and quality
were assessed by measuring the A260 and A260/A280
respectively, using the Nanodrop spectrophotometer (Peqlab,
Erlangen, Germany). 2 µg of total RNA was reverse-
transcribed using a first-strand cDNA kit with random hexamers
(Applied Biosystems, Foster City, CA) according to the
manufacturer’s recommendations. mRNA transcripts of human
MMPs-1, -2, -7, -8, -9, -12, -14, TIMPs-1, -2, -3, -4, and of
murine Mmps-7, -8, -13, Timps-1, -2, -3, -4 were quantified by
Power SYBR Green® real time-polymerase chain reaction and
with smooth muscle actin (mACTB, human and mouse,
respectively) as internal controls. Two negative controls, one
without the RNA template to confirm absence of
contaminations and the other lacking reverse transcriptase to
confirm absence of genomic DNA were included. Primer
specificity was checked by dissociation curve and gel
electrophoretic analysis. All samples were run in triplicate on
an ABI Prism 7500 Sequence Detector and software (Applied
Biosystems). The relative abundance of the target genes was
obtained by calculating against a standard curve and
normalized to an internal control. A complete list of primers is
given in Tables 1 and 2.
Table 1. Primers used for Quantitative PCR (Power SYBR
Green®) on human samples.
cDNA Primer sequence (5’ > 3’)
 (F = Forward primer; R = Reverse primer)
hMMP-1 F: CCT CGC TGG GAG CAA ACA
 R: TTG GCA AAT CTG GCG TGT AA
hMMP-2 F: CGT CTG TCC CAG GAT GAC ATC
 R: ATG TCA GGA GAG GCC CCA TA
hMMP-7 F: GCT GGC TCA TGC CTT TGC
 R: TCC TCA TCG AAG TGA GCA TCT C
hMMP-8 F:CCC AAC TAT GCT TTC AGG GAA A
 R: GCC TGA ATG CCA TCG ATG T
hMMP-9 F: GGA CGA TGC CTG CAA CGT
 R: CAA ATA CAG CTG GTT CCC AAT CT
hMMP-12 F: TGC ACG CAC CTC GAT GTG
 R: GGC CCC CCT GGC ATT
hMMP-13 F: TTC TTG TTG CTG CGC ATG A
 R: AGG GTC CTT GGA GTG GTC AA
hMMP-14 F: TCA GGG TTC CCC ACC AAG A
 R: AAC AGA AGG CCG GGA GGT A
hTIMP-1 F: CGC TGA CAT CCG GTT CGT
 R: TGT GGA AGT ATC CGC AGA CAC T
hTIMP-2 F: GGG CAC CAG GCC AAG TT
 R: CGC ACA GGA GCC GTC ACT
hTIMP-3 F: CCT GGC TAC CAG TCC AAA CAC
 R: TGC AGT AGC CGC CCT TCT
hTIMP-4 F: GCA CCC TCA GCA GCA CAT C
 R: CTG GAG ATT TTG GCC CGA AT
hß-actin (hACTB) F: GCG CGG CTA CAG CTT CA
 R: CTT AAT GTC ACG CAC GAT TTC C
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Western Blot Analysis of MMPs and TIMPs in human
tissues
50 µg total protein per sample of human lung homogenates
(as described above) were electrophoresed on a 10%
denaturing SDS-polyacrylamide gel, transferred onto
polyvinylidene difluoride (PVDF) membranes (Amersham
Biosciences, Buckinghamshire, U.K) and probed with primary
antibodies in 5% non-fat dried milk in TBS/T at 4°C, overnight.
Primary antibodies were purchased from Calbiochem (San
Diego, CA, USA) except otherwise indicated: monoclonal
antibody to human MMP-1 (1:1000, #IM35L), monoclonal
antibody to human MMP-2 (1:1000, #IM33L); rabbit polyclonal
antibody to human MMP-7 (1:5000, #PC492), monoclonal
antibody to human MMP-8 (1:1000, #IM38L), goat polyclonal
antibody to human MMP-9 (1:1000, #AF911, R&D Systems,
Minneapolis, MN), monoclonal antibody to latent and active
human MMP-13 (1:500, #IM78), monoclonal antibody to human
TIMP-1 (1:500, #IM32L), monoclonal antibody to human
TIMP-2 (1:500, #IM56L), monoclonal antibody to human
TIMP-4 (1:500; #AF974, R&D Systems, Minneapolis, MN) and
monoclonal antibody to human α-smooth muscle actin
(1:10,000; #AB6276, Abcam, Cambridge, UK). Following
incubation with respective horseradish peroxidase-conjugated
secondary antibodies to mouse, goat and rabbit IgGs (1:2000
in 5% non-fat dried milk in 1x TBS/T; DakoCytomation,
Hamburg, Germany) membranes were developed with the
Amersham ECL™ Western Blotting Detection Reagents (GE
Healthcare Ltd, Buckinghamshire, UK). Band intensity of
exposed radiographic film (Amersham Hyperfilm™ ECL GE
Healthcare Ltd, Buckinghamshire, UK) was analyzed by
densitometric scanning and quantified using AlphaEase ®FC
Imaging System (San Leandro, CA, USA). Experiments were
reproduced three times. BenchMarkTM pre-stained Protein
Ladder (Invitrogen, Carlsbad, California, USA) was used as
Table 2. Primers used for Quantitative PCR (Power SYBR
Green®) on murine samples.
cDNA Primer sequence (5’ > 3’)
 (F = Forward primer; R = Reverse primer)
mMmp-7 F: TTT GCT GCC ACC CAT GAA T
 R: ACA TCA CAG TAC CGG GAA CAG A
mMmp-8 F: GCC TGA AGA CAC TTC CAT TAC TGA T
 R: TCT CTT CCA GGT GTT CAG GTA CTG
mMmp-13 F: ATG AAG ACC CCA ACC CTA AGC
 R: CTG GTA ATG GCA TCA AGG GAT AG
mTimp-1 F: GTG GGA AAT GCC GCA GAT
 R: GGG CAT ATC CAC AGA GGC TTT
mTimp-2 F: GAT CAC TCG CTG TCC CAT GA
 R: TCT GTG ACC CAG TCC ATC CA
mTimp-3 F: TCC CCA GGA TGC CTT CTG
 R: CCA GCT TCT TTC CCA CCA CTT
mTimp-4 F: TGC TGG AAC GGA AGC TCT ATG
 R: GCA GAT GCC ATC AAC ATG CT
m-actin F: TCC TGA CGC TGA AGT ATC CGA TA
 R: GGT GCC AGA TCT TTT CCA TGT C
molecular weight markers and the following proteins were used
as positive controls (all from Calbiochem, San Diego, CA, USA,
except otherwise indicated): human rheumatoid synovial
fibroblast MMP-1 (#444208), recombinant human Pro-MMP-2
(#PF037, Oncogene Research, Cambrige, MA, USA),
recombinant human active MMP-7 (#444270), human
neutrophil granulocyte MMP-8 (#444229), recombinant human
MMP-9 (#PF024), human MMP-13 (#PF094), recombinant
himan TIMP-1 (#PF019), and recombinant human TIMP-3
(#PF095).
Histology/Immunohistochemistry
Formalin-fixed, paraffin-embedded lung tissue sections
(3µm) were routinely stained with haematoxylin/eosin (H&E),
and Masson-Trichrome stains. To assess the histological
phenotype and extent of collagen deposition, five randomly
chosen high power fields were examined from each of three
sections from 6 control and 16 IPF lungs for human tissue and
from 3–5 lungs per time point for murine tissues. Standard
immunohistochemistry was performed to localize MMP-13 and
MMP-7 on human and mouse lung tissue sections,
respectively. After deparaffinization and rehydration,
endogenous peroxidise activity was quenched by treating
tissue sections in 3% H2O2 in methanol. Antigens were
retrieved by microwaving for 20 minutes in 10mM citrate buffer,
pH 6.0 and cooling at RT. Sections were washed with
phosphate-buffered saline (PBS, pH 7.4) and
immunohistochemistry performed using the Labelled-[strept]
Avidin-Biotin (LAB-SA) method (ZYMED® LAB-SA System,
ZYMED® Laboratories, CA) according to the manufacturer’s
recommendations. After blocking non-specific background,
sections were incubated at 4°C overnight with mouse anti-
human MMP-13 (5µg/ml, #MAB13424, Chemicon) [human] or
goat anti-mouse MMP-7 (15µg/ml, #AF2967, R&D Systems)
[murine]. After three washes with PBS, a biotinylated
secondary anti-Ig was applied followed by the streptavidin-
peroxidase conjugate and visualized by adding the substrate
chromogen solution. Stained sections were counterstained with
haematoxylin; slides were dehydrated with graded series of
alcohol, cleared in xylene and mounted in HistomountTM. For
negative control slides, the primary antibody was replaced by
non-immune serum.
Immunohistochemistry (IHC) for MMPs combined with
in-situ-zymography (ISZ)
In order to compare the MMP antigen signal with the
collagenolytic/gelatinolytic activity in the tissue,
immunohistochemical localization of MMPs was performed on
10µm cryostat sections of human lungs followed by in-situ-
zymography [20,21]. Cryostat sections were air-dried for 1 hour
at RT and fixed with ice cold acetone for 10 min at RT. The IHC
procedure for the desired antigen was performed according to
standard procedures using a fluorescently labeled secondary
antibody (rhodamine RedTM-X-conjugated anti mouse IgG and
anti-goat IgG, respectively, Jackson ImmunoResearch
Laboratories, Newmarket, UK, 1:200, 1h at room temperature).
The following antibodies were used: mouse monoclonal anti-
MMP1 (5µg/ml, #IM35L, Calbiochem), mouse monoclonal anti-
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MMP-2 (10µg/ml, #IM33L, Calbiochem), mouse monoclonal
anti-MMP-8 (10 mg/ml, #IM38L, Calbiochem), goat polyclonal
anti-MMP-9 (15µg/ml, #AF911, R&D Systems), and mouse
monoclonal anti-MMP-13 (25µg/ml, MAB511, R&D Systems).
For ISZ, sections were overlaid with 1% low gelling
temperature (LGT) agarose (BioWhittaker Molecular
Applications, Rockland, ME, USA) containing 100µg/ml highly
quenched FITC-labeled DQ-collagen or DQ-gelatin (Molecular
Probes), covered with a coverslip and gelled at 4°C. Sections
were incubated at 37°C for 12 hours and examined. Control
incubations were performed on serial cryostat sections by
adding 30mM Captopril (Sigma) to the incubation medium. The
presence of auto-fluorescence in sections was tested by
incubating in agarose-containing medium lacking DQ-collagen
or DQ-gelatin. Nuclei were counterstained by adding 1 µg/ml 4’,
6-diamino-2-phenylindole [DAPI] (Invitrogen) to the incubation
medium. Sections were analyzed by comparing: (a) the
localization of the fluorescence of FITC with that of rhodamine
red; (b) the fluorescence of FITC formed after incubation in the
presence of the DQ substrate with that produced after
incubation in the absence of DQ substrate or in the presence of
the DQ substrate and MMP inhibitors. For each MMP antigen,
five high power fields were examined from each of three
sections from 6 control lungs and 8 IPF patient lungs.
Statistical analyses
Statistical analyses were performed employing the Student’s
T test and Wilcoxon test or the nonparametric Kruskal-Wallis
test. A p < 0.05 was considered statistically significant.
Results
Hydroxyproline levels are increased in IPF versus
control lung tissue
As compared with control lungs, a moderate increase in
collagen content was observed in two more different peripheral
regions of IPF lungs (Figure 1).
Upregulation of collagenases MMP1 and 13 in IPF
As compared with control lungs mRNA expression of the
collagenases MMP-1 and MMP-13 was greatly increased in
IPF lung tissue (44.8 fold, p<0.01 and 57.1 fold, p<0.001,
respectively). In addition, as previously published [22], MMP-7
mRNA expression of IPF patients was upregulated 11.8 fold
(p< 0.01; Figure 2A). Expression levels of MMP -2, -8, -9, -12
and -14 (Figure 2A) were not significantly different between IPF
and control lungs. Among the TIMPs, only TIMP-4 was
significantly altered at the mRNA level, with a 2.5 fold reduction
in IPF lungs (Figure 2A). At the protein level, a significant
upregulation in IPF lungs was observed for MMP-1 (~2 fold),
MMP -2 (~2 fold), MMP-7 (~5.5 fold), MMP-9 (~2 fold), and
MMP-13 (~2 fold; Figure 2B). In contrast, MMP-8 protein
expression was reduced (Figure 2B). None of the TIMPs
showed a significantly different expression at the protein level
(data not shown).
We demonstrated a high abundance of active MMP-13
protein in IPF versus control lungs (Figure 2C).
Immunohistochemical analysis to identify the cellular source
showed an intense staining for MMP-13 in alveolar and
bronchiolar epithelium, alveolar septae and in interstitial spaces
of IPF lungs (Figure 2E and 2F).
In-situ-zymography reveals intense collagenolytic
activity in IPF
In-situ-zymography together with immunohistochemistry was
used to determine the co-localization of collagenolytic activity
with MMP1, MMP8 and MMP13 protein expression. In control
lung tissues, MMP-1, MMP-8 and MMP-13 antigens were
predominantly expressed in macrophages and septal cells, and
only moderately co-localized with collagenolytic activity (Figure
3B, D, F). The MMP-13 antigen signal was weak and weakly
co-localized with collagenolytic activity, which probably
supports our data showing more of the proform than the active
form of MMP-13 protein in homogenates of control lungs.
In IPF lung tissue, however, abundant MMP-1 and -13
protein and collagenolytic activity was evident. The MMP-1
antigen was consistently seen at higher levels in the septae
and scar regions rather than in the airways (Fig. 3A B, C, D).
MMP-8 antigen signal was rather weak, with a dot-like
distribution pattern. Although MMP-8 co-localized with
collagenolytic activity in septae, (and to some extent in the
airways and the surrounding tissue), a higher antigen signal
was seen in intraluminal cells (Figure 3C). The antigen signal
for MMP-13 was clearly much more pronounced along the
airways of IPF lungs and co-localized with the collagenolytic
activity in these areas (Figure 3E). The green fluorescence
signal as measured by in situ zymography was specific for
collagenolytic activity. Control experiments in the presence of
30mM Captopril completely blocked the MMP-mediated
cleavage of the substrate (Figure 3G). Similarly, image
acquisition with identical microscopic settings in lung sections
incubated with medium lacking FITC-labelled collagen
forwarded no measurable autofluorescence (data not shown).
In addition, whereas we observed no difference in MMP-9
activity between IPF and control lungs (Figure 4A/C), MMP-2
activity was clearly increased in SDS-PAGE gelatin
zymography analysis of IPF lungs (Figure 4A/B). Control
experiments employing the MMP inhibitor ETDA showed no
lysis of the substrate (data not shown). Since the gelatinases
have overlapping substrate specificities [7,21], we employed
gelatin in-situ-zymography together with immunohistochemistry
in order to correlate MMP-2 protein expression with
gelatinolytic activity. In control lung tissues (not shown in
detail), MMP-2 and MMP-9 antigen signals localized mostly to
airways and macrophages and weakly co-localized with
gelatinolytic activity. In IPF lungs (Figure 4E), MMP-2 antigen
signal was dot-like in pattern, localized mostly to alveolar and
luminal cells and co-localized with gelatinolytic activity in the
interstitial space and in hyperplastic epithelia, underscoring the
contribution of MMP-2 to the matrix remodeling process in
hyperplastic epithelia. MMP-9 antigen also showed a dot-like
expression pattern, localized to airways and lung parenchyma,
but weakly co-localized with gelatinolytic activity (see Figure
4G).
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MMP-13-/- mice develop exaggerated inflammation
following bleomycin challenge
To further examine the role of MMP-13 in lung fibrosis we
utilized the bleomycin model and characterized the
inflammatory response in MMP-13-/- and WT mice at various
time points after bleomycin challenge (see Figure 5A). Likewise
to their littermate WT controls, MMP-13-/- mice exhibited
elevated total BALF cell counts (p< 0.05), which was largely
caused by an enhanced influx of granulocytes and lymphocytes
into the alveolar space. However, this inflammatory response
was more pronounced in MMP-13-/- mice. Histological
examination revealed an essentially normal lung architecture in
absence of bleomycin (Figure 5B & 5C). Seven and 14 days
after bleomycin challenge, however, both, WT (Figure 5D & 5F,
respectively) and MMP-13-/- mice (Figure 5E & 5G,
respectively) developed patchy areas of inflammation
throughout the lung parenchyma, with MMP-13-/- mice
displaying a more severe and longer lasting inflammatory
response (5D & E, d7; 5F&G, d14). In accordance with the
observations made in BALF, septal infiltration with lymphocytes
and neutrophils was more prominent in MMP-13-/- with
predominance in the subpleural and peribronchial areas
(Figure 5D–G).
Gelatinolytic activity in bleomycin-treated MMP-13-/- mice
BALF recovered from WT and MMP-13-/- mice was examined
for gelatinase activity by gelatin substrate zymography. No
activity was observed in control mice. In response to bleomycin
challenge, however, increased gelatinolytic activity was
observed in WT mice and MMP-13-/- mice, with a peak at d7
and a subsequent decline thereafter. The time course and
regulation of gelatinolytic activity appeared essentially identical
between MMP-13-/- and WT mice (see Figure 6A). Control
experiments employing EDTA completely blocked lysis of the
substrate (data not shown)
Figure 1.  Increased collagen content in IPF lungs.  Lung tissue was taken from 3 different regions of IPF patients (from
peripheral to more hilar sites) and analyzed for collagen content. Hydroxyproline content of lung tissue is indicated for IPF tissue
samples (n=8 each) versus non-utilized donor lungs (n=6). Mean data from three independent experiments per each subject are
given as scatter dot-plot, wherein the horizontal line within each group represents the mean value. The results did not reach
statistical significance.
doi: 10.1371/journal.pone.0073279.g001
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MMP-13-/- mice show more extensive lung fibrosis in
response to bleomycin administration
As compared with WT mice, MMP-13-/- mice exhibited
augmented lung fibrosis 28days after bleomycin challenge, as
evident from significantly increased collagen staining and
hydroxyproline content (Figure 6). Similar results were
observed in the lungs at 14d after bleomycin treatment (data
not shown). In line with this observation, lung compliance of
bleomycin-challenged MMP-13-/- mice on d28 was significantly
decreased as compared with bleomycin-challenged WT
littermates (see Figure 6J).
Expression of MMPs and TIMPs in MMP-13-/- and WT
mice
In MMP-13-/- and WT mice, the influence of bleomycin on the
expression pattern of MMPs and TIMPs and a possible
compensation for the loss of MMP-13 by other MMPs was
investigated. As depicted in Figure 7A, MMP-7 mRNA was
upregulated in bleomycin-challenged WT and MMP-13-/- (d28),
with a significantly higher expression in WT animals (p=
0.0037). This finding was also observed for other time points
post bleomycin challenge (data not shown).
Immunohistochemical staining for MMP-7 further corroborated
Figure 2.  Collagenases are upregulated in IPF lungs versus donor lungs.  Peripheral lung tissue samples from IPF (n=16) and
controls (n=6-8, 6 lung donors plus additional 2 control RNA) were analyzed for MMP and TIMP mRNA (quantitative PCR, A) and
protein content (Western Blots, B, C) and for MMP13 immunohistochemistry (D). (A) mRNA content of each MMP/TIMP is indicated
by target mRNA to human β-actin ratio. (B) Protein content of each MMP/TIMP is given as the mean normalized integrated density
value (IDV) compared with that of actin as loading control. Mean value ± SEM is given. For each patient triplicate determination
were undertaken. Data presented are from three independent experiments. Significance level is indicated by * (p< 0.05), ** (p<0.01)
and *** (p<0.001) compared with normal lungs for mRNA and healthy donor lungs for protein expression. (C) Representative
immunoblot demonstrating increased protein expression of both the latent and active form of MMP-13 in IPF (right lanes) versus
controls (organ donors, left 3 lanes). (D) Immunohistochemistry for MMP-13 in controls (organ donors, D) versus IPF lungs (E, F).
Whereas only weak MMP-13 immunoreactivity was observed in alveolar macrophages and bronchial epithelial cells in the control
lungs, increased MMP-13 expression was easily detected in alveolar and bronchiolar epithelial cells (arrow), alveolar macrophages,
but also in interstitial spaces of IPF lungs. Scale = 100µm. (F) Higher power view of E showing abundant MMP-13 immunoreactivity
(arrows); scale = 50µm.
doi: 10.1371/journal.pone.0073279.g002
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this finding (Figure 7B). In contrast, an elevated baseline
MMP-8 mRNA expression was observed in healthy MMP-13-/-
mice, that was further induced in both, MMP-13-/- and WT mice,
after bleomycin administration, however, with much higher
mRNA levels in knockout mice (Figure 7C). As expected,
MMP-13 transcripts were not observed in MMP-13-/- mice, but
expression was greatly induced in WT mice receiving
bleomycin (Figure 7D). The mRNA transcripts of TIMPs 1-4
(Figure 7E) were significantly elevated in MMP-13-/- at baseline
and increased after bleomycin challenge.
Figure 3.  In-situ-zymography combined with MMP antigen detection.  Control (B, D, F) and IPF (A, C, E, G) lung samples
obtained in the surgical theatre were analyzed for collagenase activity (in-situ-zymography, green) and for MMP-1 (upper panel), -8
(middle) and -13 (lower panel) antigen signal (immunohistochemistry, red) within the same cryostat section. Nuclei were stained
with DAPI (blue). White arrows show the co-localization of collagenolytic activity with: MMP-1 antigen signal in the septal and scar
regions (A); MMP-8 antigen signal in septae (C); and MMP-13 antigen signal along the airways, alveolar epithelial cells and cells
lining fibroblastic foci (E). Section G represents a negative control and shows an IPF section analyzed for collagenase activity in
presence of 30mM captopril. Representative sections are given. Original magnification = 10X, 20X and 40X; scale = 100µm.
doi: 10.1371/journal.pone.0073279.g003
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Discussion
In the present study, the expression pattern of several MMPs
and TIMPs was analyzed in explanted IPF as compared with
control lungs and the spatial distribution of MMP-1, -8, -13 and
MMP-2 and -9 antigen signal was correlated with the
collagenolytic and gelatinolytic activity. Among all MMPs and
TIMPs studied in lung homogenates, only the collagenases
MMP-1 and MMP-13, and MMP-7 were found to be
significantly upregulated at the mRNA and protein level.
Figure 4.  Gelatinolytic activities in IPF versus donor (control) lungs.  A–C: Representative zymogram of gelatin substrate
zymography of homogenates of control and IPF lungs (A); lytic zones of MMP-2 and MMP-9 activity appear white over the dark
background. Densitometric analysis of pro- and active-MMP-2 activity (B); and of pro- and active MMP-9 activity (C). **p < 0.01 IPF
compared with controls.
D–G: Representative photomicrograph of H&E stain of cryo-sectioned IPF lung tissue (D) and (F), and gelatinase in situ
zymography combined with immunohistochemistry for MMP-2 and MMP-9. MMP-2 antigen signal was dot-like in pattern, localized
mostly to alveolar and luminal cells and co-localized with gelatinase activity in hyperplastic epithelia (E, G). MMP-9 antigen also
showed a dot-like pattern of expression, localized both to the airways and lung parenchyma, and but with limited co-localization with
gelatinase activity (g) (Blue = nuclei, green = gelatinolytic activity, red = MMP-2 antigen in (E) or MMP-9 antigen in (G). Original
magnification = 10X, scale = 100µm.
doi: 10.1371/journal.pone.0073279.g004
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Although the gelatinases MMP-2 and MMP-9 were found to be
unchanged at the mRNA level, a roughly twofold increase was
encountered at the protein level in IPF homogenates.
Unexpectedly, TIMPs-1 -4 were not significantly increased in
IPF homogenates, neither at the mRNA nor at the protein level.
At a quick glance, this observation is in contrast to the
observed increase in hydroxyproline content, especially in the
subpleural areas of IPF, and our data go against the concept
that far-reaching blockade of MMP activity by overwhelming
TIMP levels, as suggested previously [23], is the underlying
principle of the increase in ECM content in IPF. There might be
some methodological limitations when analyzing MMPs and
TIMPs in lung tissue. Extraction from tissue is reported to be
difficult and several TIMPs, such as MMP-1, MMP-2, and
MMP-9 are tightly bound to the ECM [24]. In addition, the
different texture of IPF vs. control tissue might affect extraction
and be associated with some uncertainty whether all MMPs
and TIMPs are extracted. Regardless of such theoretical
limitations and despite our restriction to only study MMP-1, -2,
-8, -9 and -13 at the level of in-situ-zymography, the most
reasonable explanation for our observations is, however, that
either production and deposition of ECM compounds exceeds
the capacity of the ECM degradation machinery or that spatial
distribution of proteolytic activity is uneven or both [25]. Indeed,
our in-situ-zymography data do suggest that collagenolytic and
gelatinolytic activities are not exclusively co-localized with the
respective MMP antigen signals in the lung tissues, suggesting
free and overwhelming MMP activity within the airways and
Figure 5.  Augmented inflammatory reaction in MMP-13-/- mice following bleomycin challenge.  MMP-13 -/- and respective WT
mice were challenged with saline (Control) or with 5U/kg bw bleomycin and investigated 7, 14 and 28days after challenge.
(A) Given are the total cell counts and the macrophage, neutrophil and lymphocyte numbers in bronchoalveolar lavage fluids.
Results are presented as mean ± SEM, n = 4-5 per group. *p< 0.05 compared with control, **p< 0.01 compared with control, # p <
0.05 compared with corresponding WT value.
(B) - (G) Histological appearance of WT (B, D, F) and MMP-13-/- (C, E, G) lungs in response to saline application (Controls, B, C) or
challenge with bleomycin at d7 (D, E) and d14 (F, G). Given are representative lung sections stained with haematoxylin and eosin.
Control mice (B, E) imposed with normal alveolar architecture. 7d (D and E) and 14d (F and G) after bleomycin treatment, WT and
MMP-13-/- mice lungs showed heterogeneous distortion of peribronchiolar region, and MMP-13-/- mice displayed numerous
inflammatory cells throughout the lung parenchyma (Original magnification: B and C 10X; D-G 4X and 20X).
doi: 10.1371/journal.pone.0073279.g005
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Figure 6.  Bleomycin induced lung fibrosis is more severe in MMP13 -/- mice.  A–F: MMP-13-/- and WT mice were exposed to
saline (control) or bleomycin and analyzed for extent of lung fibrosis 28 days later. Representative lung sections from WT (A, B, C)
and MMP-13-/- (D, E, F) lungs were stained with haematoxylin and eosin (A, B, D, E, original magnification = 40X) and Mason-
Trichrome (C, F, original magnification = 40X) stain for collagen.
G: Hydroxyproline content of WT and MMP-13-/- mice lungs 7, 14, and 28 days after saline (control) or bleomycin challenge.
Duplicate analysis was undertaken per each lung sample. Data are presented as mean ± SEM out of 5 lungs per group. *p <0.05
compared with WT control; # p<0.05 compared with MMP-13-/- control. Differences in p-value between WT and MMP13-/- mice per
each time point are directly indicated in the figure.
H: Representative gelatin substrate zymogram of BALF 7, 14 and 28 days after intra-tracheal administration of bleomycin or saline
to MMP-13-/- and WT mice. Lane1: molecular weight marker, lanes 2, 4, 6, 8: MMP-13 WT; lanes 3, 5, 7, 9: MMP-13-/- ; Lane 10
recombinant MMP- 2 and -9.
J: Lung Compliance of saline-treated (control) and 28d bleomycin treated MMP-13-/- and WT mice. The lung compliance of
MMP-13-/- mice on d28 after bleomycin challenge was significantly decreased as compared with d28 bleomycin challenged WT
mice. n = 3 per group. Results are presented as mean ± SEM.
doi: 10.1371/journal.pone.0073279.g006
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weaker activity in the scarring regions. Interestingly, such an
observation may serve as an important explanation for the
Figure 7.  Expression of MMPs 7, 8, 13 and TIMPs in lungs of bleomycin challenged MMP-13-/- and WT mice.  MMP-13-/- and
WT mice were exposed to saline (control) or bleomycin and analyzed for Mmp-7 (A), Mmp-8 (C), Mmp-13 (D), and TIMPs1-4 (E) at
the transcriptional level using quantitative RT- PCR. MMP-7 immunostaining (B) confirmed reduced MMP-7 expression on protein
level in distal airways of MMP-13-/- versus WT mice in response to bleomycin challenge. Red arrows point to MMP-7 antigen
immunolocalized with macrophages and type I and II alveolar epithelial and bronchial epithelial cells, in particular in the
peribronchial region of bleomycin-treated MMP-13 WT mice. No MMP-7 staining was observed in the respective control lungs. Data
are given as mean ± SEM from 5 mice per treatment group (A, C, D, E) or as representative immunohistochemistry from at least 3
lungs per group (B). * p< 0.05, ** p< 0.01, ***p< 0.001 compared with the untreated WT control; # p< 0.05, # # p< 0.01, # # # p< 0.001
compared with the untreated MMP-13-/- control. Differences in p-value between WT and MMP-13-/- mice per each time point are
directly indicated in the figure. Scale bars: 100µm (Control), 50µm (Bleomycin d28).
doi: 10.1371/journal.pone.0073279.g007
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development of honeycomb cysts, an obviously inappropriate
loss of lung architecture and puzzling feature of IPF and many
other progressive forms of lung fibrosis [16,26,27].
Another novel finding of this study is the observation of the
highly upregulated pro- and active MMP-13 and MMP-1 protein
in IPF patients. MMP-13 protein was localized to alveolar and
bronchiolar epithelial cells, alveolar macrophages, alveolar
septae and interstitial tissues of remodeled lung tissue. This is
an interesting finding, as the group of Selman [23]
demonstrated that MMP-1 was localized to bronchiolar
epithelial cells, but not the interstitium, where abundant ECM is
found. Ortiz and colleagues [28] previously showed that the
increased MMP-13 expression in lungs of silica-treated TNF
receptor-deficient mice was primarily localized to the cytoplasm
of macrophages inside silicotic nodules.
MMP-1 and MMP-13 are major proteinases with substrate
specificity towards interstitial fibrillar collagen and gelatin,
preferentially cleaving type-I and type-II collagen. Drawn
against this background and the recently shown involvement of
MMP-13 in bone remodeling defects in skeletal diseases [29],
in mediating collagen breakdown in atherosclerotic plaques
[30], and in the reduction of liver fibrosis after CCl4 injury [15],
we hypothesized that MMP-13 might also play a significant role
in the pathogenesis of pulmonary fibrosis. To further
characterize the role of MMP-13 in lung fibrosis we employed
the bleomycin model and observed an exaggerated early
inflammation in the MMP-13-/- mice, which was attributable to a
progressively increasing neutrophilic response. Contrary to our
findings, previous studies reported less neutrophil
accumulation in MMP-9-/- [31] and MMP-12-/- [18] mice after
bleomycin treatment, whereas in WT mice a remarkable
infiltration of neutrophils and lymphocytes characterized the
initial inflammatory response to bleomycin. The underlying
reason for the observed hyperinflammation in MMP-13-/- mice is
currently not clear and deserves further analysis.
Starting at d14 after bleomycin challenge, an augmented
fibrotic response was encountered in MMP-13-/- mice, however,
it is currently unclear if this was caused by the more extensive
inflammation or the pure absence of MMP-13. This holds
especially true when considering that MMP-7 was found to be
downregulated and the TIMPs were not found to be
dramatically altered in MMP-13-/- versus WT mice in response
to bleomycin challenge. One intriguing interpretation of our
experimental data would also be a compensatory upregulation
of MMP-8 in order to substitute for missing MMP-13.
Somewhat in line with such reasoning, Raulo and colleagues
[32] had previously reported a positive correlation between
immunoreactivity of MMP-8 and MMP-13 and the amount of
degradation of type-I collagen. Macrophages and epithelial
cells were observed as the major cellular sources of these
MMPs (-8 and -13). Supporting the hypothesis of reciprocal
compensation of MMP deficiency, Lindsey and group [33]
reported significantly lower levels of MMP-13 in the left
ventricle of MMP-7-/- mice, whereas pro-MMP-8 levels were
elevated. Although purely speculative at present, these
observations together with our data suggest that MMP-13 and
MMP-7 are regulated synergistically in fibrotic repair, with a
consecutive downregulation of each MMP once the other is
absent. However, further studies are required to define such a
possible interaction.
In summary, in order to better define spatial regulation and
nature of MMP activity in the process of fibrotic repair in IPF,
we could firstly show that TIMPs are not excessively
upregulated as compared with MMPs in IPF lungs and that the
collagenolytic activity of IPF tissue is higher as compared with
control lungs. Hence, increased collagen deposition in IPF
seems to be largely due to excessive matrix synthesis and
deposition rather than blockade of MMPs. Secondly,
collagenolytic and gelatinolytic activities do not colocalize
completely with single MMP antigen signals in IPF lung tissues
and collagenolytic activity appeared more prominent within the
airways as compared with scar regions. Thirdly, our data
suggest that MMP-13 plays a significant, if not pivotal, role in
ECM remodeling in IPF, as this collagenase is dramatically
upregulated in tissues from IPF patients and as excessive lung
fibrosis is encountered in bleomycin challenged MMP-13-/-mice.
On the one hand MMP-13 may still help to limit ECM deposition
in areas of dense fibrosis, on the other hand excessive
MMP-13 activities in the airways may promote development of
honeycomb cysts, similar to the induction of emphysema
formation in MMP-1 overexpressing mice [34].
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